Effects of reducing the lactate and glucose content of PD solutions on the peritoneum. Is the future GLAD?

NDT Plus

Volumn 1, Issue SUPPL. 4, 2008, Pages

  Krediet, Raymond T ^a,b   Zweers, Machteld M ^a   Van Westrhenen, Roos ^a   Zegwaard, Agnes ^a   Struijk, Dirk G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Glucose; Glycerol; Lactate; Peritoneal dialysis solutions; Pyruvate

Indexed keywords

AMINO ACID; BICARBONATE; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; GLYCEROL; HYPERTONIC SOLUTION; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PYRUVIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; FIBROSIS; HYPOXIA; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RAT; VASODILATATION;

EID: 57349155123     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfn126     Document Type: Conference Paper

References (26)

1. Heimburger O, Waniewski J, Werynski A et al. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495-506
2. Smit W, Schouten N, Van Den Berg N et al. for the Netherlands Ultrafiltration failure study group. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross sectional study. Perit Dial Int 2004; 24: 562-570
3. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000; 20(Suppl 4): S22-S42
4. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27
5. Mateijsen MAM, Van Der Wal AC, Hendriks PMEM et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525
6. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
7. Honda K, Nitta K, Horita S et al. Morphological changes in the vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-176
8. Di Paolo N, Sacchi G. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy. Perit Dial Int 1989; 9: 41-45
9. Numata M, Nakayama M, Nimura S et al. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116-122
10. Davies SJ, Phillips L, Naish PF et al. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046-1051
11. Zweers MM, de Waart DR, Van Der Wal AC et al. Structural and functional changes of the peritoneum in a chronic peritoneal infusion model in the rat. Thesis, University of Amsterdam, 2000
12. Zweers MM, Splint L, Krediet RT et al. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16: 651-654
13. Hekking LHP, Zareie M, Driesprong BAJ et al. Better preservation of peritoneal morphologic features and defense in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12: 2775-2786
14. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-1265
15. Mahiout A, Brunkhorst R. Pyruvate anions neutralize peritoneal dialysate toxicity. Nephrol Dial Transplant 1995; 10: 391-394
16. Shostak A, Gotloib L, Kushnier R et al. Protective effect of pyruvate upon cultured mesothelial cells exposed to 2 mM hydrogen peroxide. Nephron 2000; 4: 362-366
17. Beyer-Mears A, Diecke FP, Mistry K et al. Effect of pyruvate on lens myo-inositol transport and polyol formation in diabetic cataract. Pharmacology 1997; 55: 78-86
18. Williamson JR, Chang K, Frangos M et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42: 801-813
19. Dvorak HF, Brown LF, Detmar M et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol 1995; 146: 1029-1039
20. Tilton RG, Kawamura T, Chang KC et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99: 2192-2202
21. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487
22. Tanaha Y, Katoh S, Hori S et al. Vascular endothelial growth factor in diabetic retinopathy. Lancet 1997; 349: 1520
23. Zweers MM, de Waart DR, Smit W et al. Growth factor VEGF and TGF-β in peritoneal dialysis. J Lab Clin Med 1999; 134: 124-132
24. Zweers MM, Struijk DG, Smit W et al. Vascular endothelial growth factor in peritoneal dialysis. A longitudinal follow-up. J Lab Clin Med 2001; 137: 125-132
25. Van Westrhenen R. Understanding and preventing the peritoneal damage caused by conventional dialysis solutions. Thesis, University of Amsterdam, 2005
26. Zareie M, Hekking LHP, Welten AGA et al. Contribution of lactate buffer, glucose and glucose degradation product to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18: 2629-2637